Quarter
Charts🇺🇸US Markets

SERES THERAPEUTICS, INC.

MCRB

CIK 0001609809 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$438K
Gross Profit
$438K

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0ROIC -168.9% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 2.56 (above 1.5 = solid)
  • Leverage
    100D/E -1.26 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.01x (1.0+ = capital-efficient)
  • Growth
    0Insufficient data
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project MCRB's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$1.68
Total enterprise IV
$15M
Diluted shares
0.01B
Terminal PV
$11M (72% of total)
Year-5 FCF
$1M
YearProjected FCFDiscounted PV
+1$934K$849K
+2$1M$834K
+3$1M$819K
+4$1M$804K
+5$1M$789K
Terminal$17M$11M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$252K
investment in PP&E
Stock-based comp (TTM)
$11M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$138M
everything owned
Total liabilities
$94M
everything owed
Stockholders' equity
$44M
shareholder claim
Net debt
$64M
LT debt minus cash

Recent performance · 48 quarters

Revenue
$438K
Net Income↓-90.8% -$81M
$8M
Free Cash Flow↑+67.8% +$61K
$-29K
Operating Margin
-6403.7%

Drill down

MCRB Sankey

See SERES THERAPEUTICS, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

MCRB Charts

48 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

MCRB Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics